There is no difference in safety and efficacy with Tirofiban or Eptifibatide for patients undergoing treatment of large vessel occlusion and underlying intracranial atherosclerosis-Reference-Cited by-同舟云学术

There is no difference in safety and efficacy with Tirofiban or Eptifibatide for patients undergoing treatment of large vessel occlusion and underlying intracranial atherosclerosis

Published:2021-03 Issue: Volume:23 Page:100927
ISSN:2214-7519
Container-title:Interdisciplinary Neurosurgery
language:en
Short-container-title:Interdisciplinary Neurosurgery

Author:

Movva Hari,Rabah Rani,Tekle Wondwossen,Georgiadis Alexandros,Preston Laurie,Kotta Hari,Hassan Ameer E.^ORCID

Publisher

Elsevier BV

Subject

Neurology (clinical),Surgery

Reference17 articles.

1. Cost and effectiveness of glycoprotein IIb/IIIa-receptor inhibitors in patients with acute myocardial infarction undergoing percutaneous coronary intervention;McCollam;Am. J. Health Syst. Pharm.,2003

2. Tissue-type plasminogen activator as a therapeutic target in stroke;Gravanis;Expert Opin. Ther. Targets,2008

3. Tirofiban combined with rt-PA intraarterial thrombolysis improves the recanalization rate of acute middle cerebral artery occlusion in rabbits;Yu;Eur. Rev. Med. Pharmacol. Sci.,2018

4. Safety and preliminary efficacy of early tirofiban treatment after alteplase in acute ischemic stroke patients;Li;Stroke,2016

5. Chemical structures and mode of action of intravenous glycoprotein IIb/IIIa receptor blockers: a review;Hashemzadeh;Exp. Clin. Cardiol.,2008

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Integrins as Drug Targets in Vascular and Related Diseases;International Journal of Drug Discovery and Pharmacology;2024-06-21

2. Glycoprotein IIb/IIIa inhibitors for the neurointerventionalist;Interventional Neuroradiology;2021-05-04